Stockreport

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 [Yahoo! Finance]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active p [Read more]